SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innoste…
Category: News
Lock In Instant Definition and Volume with COVERGIRL’s NEW Mascara
NEW YORK–(BUSINESS WIRE)–Get ready to lock in lashes that feel stronger and protected with COVERGIRL’s latest addition to the Lash Blast portfolio. Say hello to NEW Lash Blast Bond Mascara, formulated to deliver instant definition and up to 5x visibl…
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release secon…
Samenvatting: Doorbraak in de oogheelkunde! Heng Qin® (perfluorohexyloctaan oogdruppels) van Hengrui goedgekeurd als eerste behandeling voor droge ogen geassocieerd met MGD
JIANGSU, China & HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (‘Hengrui Pharma’), een wereldwijd farmaceutisch bedrijf gericht op wetenschappelijke en technologische innovatie, en Novaliq GmbH (‘Nov…
Riassunto: Novità nell'oftalmologia! Heng Qin®, il collirio al perfluorohexyloctane realizzato da Hengrui è stato approvato come primo trattamento per la sindrome dell'occhio secco associata alla MGD
JIANGSU, Cina, HEIDELBERG, Germania e CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), azienda farmaceutica globale incentrata sull’innovazione scientifica e tecnologica, e Novaliq GmbH (“Novaliq”), un’az…
Resumen: Gran avance en oftalmología: Heng Qin® de Hengrui (colirio de perfluorohexiloctano) aprobado como primer tratamiento para la sequedad ocular asociada a la Disfunción de las glándulas de Meibomio
JIANGSU, China y HEIDELBERG, Alemania y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Jiangsu Hengrui Pharmaceuticals Co. Ltd. («Hengrui Pharma»), una compañía farmacéutica internacional centrada en la innovación científica y tecnológica, y Novaliq GmbH (…
Study Finds Wide Pay Gaps in Eye Care
Inconsistent fees paid to doctors and facilities show the disadvantage independent clinicians face in the market. Medscape Medical News
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
GENEVA–(BUSINESS WIRE)–Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Efficacy and Toxicity Seen With MIRV in Ovarian Cancer
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News
America’s Favorite Sports Pose a Risk for Orbital Fractures
Sports such as baseball, softball, and bicycling are the leading causes of orbital fractures in the US, particularly among adolescents and men, a retrospective cohort study shows. Medscape Medical News
Novartis Drug Cosentyx Fails Late-stage Trial for Artery Disease
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the… Reuters Health Information
Despite Majority of Americans Struggling with the Impact of Poor Eyesight and Eye Health on Daily Life, More than Half Are Delaying or Avoiding Eye Care
NEW YORK–(BUSINESS WIRE)– #EyeCare–New Versant Health study finds 86% of Americans would seek eye exams if linked to overall health. Education, access and tech drive vision benefit use.
Eye Surgeon Raises Red Flag on Popular Lash Trend
Eyelash extensions are applied near the delicate ocular surface and may lead to serious complications like dry eye, keratitis, and lash misdirection. Medscape
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The…
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+L…
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics annonce une avancée majeure dans son nouveau partenariat de fabrication avec Catalent
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les mala…
Omidenepag Promising Against Glaucoma in Real-World Study
Eye drops containing 0.002% omidenepag isopropyl can safely reduce intraocular pressure in patients with newly diagnosed primary open-angle glaucoma, according to a real-world study. Medscape Medical News
Age Ups Risk for Acute Dacryocystitis in Blocked Tear Ducts
Acute dacryocystitis is common in women, and the risk for the condition rises with age, especially in those with primary acquired nasolacrimal duct obstruction. Medscape Medical News